INTRODUCTION
Mantle cell lymphoma is an uncommon form of non-Hodgkin's lymphoma characterized by generally high relapse rate and mortality. Although translocation of CCND1 is a defining feature of the disease, the role of collaborating somatic mutations that contribute to mantle cell lymphoma remains to be further defined 1-3 .
Cancers have traditionally been classified based on their anatomic tissue of origin.
Hematopoietic malignancies (leukemias and lymphomas) in particular have been extensively subclassified beyond tissue of origin, based upon the specific point in the B cell differentiation stage from which they are thought to arise. Thus, the study of these tumors enables the direct comparison between the normal stages of cell differentiation and tumors that are thought to arise from them.
As we better understand the genetic abnormalities underlying tumors, it is unclear whether the traditional methods of classifying tumors based on their tissue of origin remain useful. For instance, it has been proposed that tumors could be reclassified based on their particular mutational profiles rather than their cell of origin 4 . While some genes appear to be mutated frequently in a large number of cancers (e.g. TP53), a number of oncogenes have been found to be relatively specific to certain cancers. The lineage specificity of mutations has not been fully defined.
A number of genes related to B cell differentiation are recurrently mutated in lymphomas (e.g.
BCL6 5 , EZH2 6 ). Expression of mutant EZH2 hampers germinal center (GC) differentiation and drives aberrant proliferation 7 . However, the relationship between the differentiation stage and the development of specific mutations in cancers remains to be defined. While early efforts have attempted to characterize the association of chromatin structure to genetic alterations, they have been limited to aggregate alterations at the megabase scale 8 , or rearrangement breakpoints 9 , or known risk variants 10 . Work comprehensively defining the chromatin state of more than one normal cell type and direct association of gene mutations in tumors that arise from those normal cells has been lacking.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From The ENCODE project 11 has elucidated the chromatin structure of a number of cell types, but a similar definition of primary human mature B cells has been lacking. A particular advantage of studying mature B cells is that their relationship to leukemias and lymphomas is far better defined compared to other cell types (e.g. those corresponding to solid tumors). In this study, we sought to better understand the role epigenetic alterations that determine chromatin structure play in the gene expression and mutational profiles of B cell tumors.
We performed exome sequencing in 56 cases of mantle cell lymphoma to broadly identify the mutational landscape of the disease. We noted that the genetic profiles of mantle cell lymphomas were distinct from other aggressive lymphomas. We then defined the chromatin structure of the normal counterpart B cells (naïve and germinal center B cells respectively) for mantle cell lymphoma and Burkitt lymphoma by profiling their epigenetic markers using chromatin immunoprecipitation followed by sequencing (ChIP-seq) for markers H3K4me1, H3K4me3, H3Ac, H3K36me3, H3K27me3 and PolII. We found that the somatic mutational profiles of mantle cell lymphoma and Burkitt lymphomas overlapped strongly with areas of open chromatin in their normal counterpart B cells, identifying the epigenetically determined chromatin structure in normal B cells as a potential determinant in the acquisition of somatic mutations.
Thus, our data define the broad genomic landscape of mutations in mantle cell lymphoma and point to an interplay between epigenetic states in normal cells and the development of genetic alterations that lead to cancer.
METHODS

MCL sample acquisition and processing
Mantle cell lymphoma (MCL) tumors (N=56) and normal tissue (N=28) were obtained from the institutions that constitute the Hematologic Malignancies Research Consortium (HMRC) 12 .
Genomic DNA was extracted as described previously 12 . Patient tumor and normal samples were collected according to IRB guidelines. This study was conducted in accordance with the Declaration of Helsinki.
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Exome capture and library preparation
Genomic DNA was sheared to 250 bp using the Covaris S2 platform. Exome capture libraries were prepared as described previously 13 .
B cell isolation
Tonsils were obtained according to IRB guidelines from patients undergoing routine tonsillectomy at a North Carolina hospital. Mononuclear tonsillar B cells were prepared and stained as described previously. 14 Stained cells were FACs sorted into 10 million each of naive B cells (CD19+IgD+CD27-CD38+), GC B cells (CD19+IgD-CD38++), and memory B cells (CD19+IgD-CD27+CD38dim) for each chIP antibody.
Chromatin immunoprecipitation (ChIP) and sequencing library preparation
Flow-sorted B cells were cross-linked with 1% formaldehyde, pelleted, lysed, and sonicated to a median size around 200 bp. After sonication, the nuclear extract was washed and incubated overnight at 4 ºC with antibodies coupled to magnetic beads (Invitrogen, 112.03D): anti-H3K4me3 (Millipore, 07-473), anti-H3K4me1 (Abcam, ab-8895), anti-H3K27me3 (Millipore, 07-449), anti-H3Ac (Millipore, 06-599), anti-PolII (Santa Cruz, sc-899x) and anti-H3K36me3 (Abcam, ab-9050). Isotype-matched IgG control antibodies were used in parallel as negative control. The beads were washed, and the immunoprecipitated complex was eluted and reverse cross-linked at 65°C overnight. The samples were subsequently digested and purified.
Sequencing libraries were prepared using the Illumina Genomic DNA Sample Prep kit (FC-102-1001) according to the provider's protocol.
Exome data processing and analysis
Exome Sequence Alignment, Variant Calling, and Annotation Reads in fastq format 15 were pre-processed with GATK 16 to remove Illumina adapter sequences and Phred-scaled base qualities of 10 and below as described previously 17 . After GATK processing, reads were mapped to hg18 using Burrows-Wheeler Aligner (BWA 18 ), followed by Novoalign V2.06.09 (Novocraft.com). Remaining unmapped reads were clipped to 35bp to remove adapter matches in the 3' end of the read, and re-aligned with BWA.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From All alignments were output as BAM files 19 and merged using Picard (http://picard.sourceforge.net). The data will be available on dbGaP. PCR/optical duplicates were marked by Picard. Base quality recalibration was performed using GATK. To improve accuracy and quality of the calls, localized indel realignments were performed using GATK 16 . Regions that should be realigned are determined by the GATK Realigner Target Creator. Single nucleotide variant (SNV) and indel variants were called using SAMtools 20 . SAMtools mpileup was run on all cases and output to a single VCF file. Each variant was required to have an instance of genotype quality greater than 30 and read depth greater than 5. Individual SNVs and indels were annotated with gene names and predicted function using Annovar (http://wannovar.usc.edu/) 21 .
Identification of somatically acquired mutations using muTect muTect 22 was used to identify somatic mutations in the 28 MCL tumor-normal pairs. BAM files were generated as described above. muTect version 1.1.1 was executed on each tumor-normal pair.
Control exomes
In addition to NHLBI 6500 exomes (http://evs.gs.washington.edu/EVS/), 1000 Genome Project 23 , and dbSNP135 24 frequencies, we also filtered our mantle cell lymphoma variants against 189 noncancer exomes generated in-house and 256 publicly available exomes that we re-processed 25,26 . This allowed us to reduce the number of variants observed that are simply part of normal human variation.
Coverage
SAMtools 20 flagstat was used to compute the number and percent of reads that mapped to the genome. Both depth and breadth of coverage for each exome were computed using BEDTools 27 .
Sanger Sequence Validation
DNA regions of interest were amplified using primers designed to target exonic regions containing the variant, as described previously 28 . The amplified fragments were verified by For personal use only. on August 31, 2017. by guest www.bloodjournal.org From agarose gel, and reactions were purified with ExoSAP-IT using manufacturer instructions (Affymetrix, 78250).
Significantly differentially mutated genes
Differentially mutated genes were selected for further analysis by Fisher's exact test between the number of mutated and unmutated cases in Burkitt lymphoma and mantle cell lymphoma (p<0.05).
Gene pathway analysis
Using GATHER Gene Ontology annotation (http://gather.genome.duke.edu/) and GSEA MSigDB (http://www.broadinstitute.org/gsea/msigdb/index.jsp), enrichment of this set of 37 MCL mutated genes was measured in known gene lists. Enrichment was considered to be significant at an FDR q-value less than 0.05.
ChIP-seq data processing and analysis
Alignment and peak calling
The B cell ChIP-seq and mock samples were aligned to the reference human genome (hg19) using Bowtie 29 . Significantly (P<0.0001, FDR<5%) enriched peak regions were detected using the MACS software 30 using the following parameters (--nomodel, --shiftsize=100, --bw=250, --mfold=10,30, -w -S, -g hs, --pvalue=0.0001). The data will be available on GEO.
Characterizing ChIP-seq reads in gene regions
For each pair of ChIP marker and B cell sample (Naïve and GC), a score was calculated for each gene in a similar fashion to RNA-seq RPKM. Specifically, for each gene region (5 kb padded on either side), the number of aligned reads to fall in that gene region were counted using coverageBed 27 . This number is divided by the length of the gene region in base pairs, and again by the total number of aligned reads in that particular sample, to adjust for coverage differences.
The scores were multiplied by 1 billion to get to a reasonable number range and log2 transformed. Transcription start and stop sites for each gene were extracted from RefSeq. Gene region BED files, padded by 5kb on either end of the transcription start and stop sites, were
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Open chromatin calculation
The open chromatin score for each gene is defined as the sum of H3K4me1, H3Ac, and H3K36me3 individual gene scores. Differences between Naïve and GC are calculated by subtracting one cell type chromatin score from the other. Processing microarray data and selecting significant genes BL, MCL, and B cell expression CEL files were normalized together using RMA 32 .
Microarray data analysis
Differentially expressed genes between naïve and germinal center B cells were selected using a ttest p-value less than 0.05, absolute fold change greater than 1, and mean expression greater than 5.5.
RESULTS
Exome sequencing reveals recurrent genetic alterations in mantle cell lymphoma
We performed exome sequencing on 56 mantle cell lymphoma tumors, 28 with paired normal tissue (i.e. total 84 exomes). DNA was extracted from these tissues and paired end sequencing libraries were constructed, followed by exome-enrichment using a solution-based capture approach available commercially through Agilent. On average, we achieved 102-fold coverage of the targeted exonic regions. Over 90% of the targeted exons were covered at an average depth exceeding 10-fold.
Sequencing reads were mapped to the reference human genome, and high-quality mismatches were classified as synonymous and nonsynonymous variants. Nonsynonymous variants were further subclassified as missense, nonsense and small insertions/deletions (indels). Missense variants comprised the highest proportion of alterations (48.4%), whereas synonymous and nonsense variants and indels comprised 46.8%, 0.7% and 4% respectively.
We verified the accuracy of identifying genetic variants through deep sequencing by performing Sanger sequencing in the same cases for 53 distinct variants. As in our previously described work with hundreds of variants 13,17 , we found over 90% agreement between the two methods.
These results confirmed the accuracy of our methods for high throughput sequencing and identifying genetic variants.
Defining the landscape of gene mutations in mantle cell lymphoma
We initially examined the exomes of the mantle cell lymphoma cases with paired germline DNA. We identified somatic mutations affecting 537 genes in at least one tumor/germline pair among these cases. Transitions comprised the majority of the somatic variants (P<10 -3 , chisquared test). On average, we observed 32 somatic alterations per sample (range 1-61), a rate similar to that which we observed in Burkitt lymphoma cases 17 , and approximately half the rate we observed in DLBCL 13 . Upon inclusion of an additional 28 validation samples in our analysis, we identified 1189 rare variants corresponding to these 537 somatically mutated genes. These variants were not present in publicly available data from normal controls including dbSNP135 24 , the 1000 Genomes Project 23 , and available exome sequencing data from healthy individuals without lymphoma 25, 26 .
We further required each of the identified genes to have three somatically acquired and/or non synonymous rare events predicted to be functionally significant. These methods, detailed in the Supplement, allowed us to identify 37 recurrently mutated genes in mantle cell lymphoma. These genes are depicted in Figure 1a and listed in Supplementary Table 2 . The individual variants are 1 0 listed in Supplementary Table 3 . The relative frequency of synonymous and nonsynonymous variants for each gene is shown in Figure 1b . 12 of the 37 genes have been previously implicated in cancer 33 .
The most frequently mutated genes in mantle cell lymphoma were ATM (41.9%), CCND1 (14%), MLL2 (19.6%) and TP53 (18.6%). Other frequently mutated genes included known oncogenes and tumor suppressor genes such as RB1, SMARCA4, APC, NOTCH1, and UBR5. Our data also implicated a number of genes not previously associated with mantle cell lymphoma, including POT1, FAT4 and ROBO2. Silencing mutations (frameshift and nonsense mutations) comprised a sizeable fraction of the genetic events in ATM, MLL2, MLL3, RB1 and ROBO2, suggesting that those alterations result in a loss of function in mantle cell lymphoma.
Pathway and gene set analysis of the significantly mutated genes reveals a crucial role for many of these genes in cell cycle regulation (SMC1A, POT1, RB1), cell adhesion (FAT4, DLC1, CDH8), development (ROBO2, ANK2, CTNNA2), and chromatin modification (SMARCA4, MLL2, MLL3, WHSC1). Figure 1c illustrates the links between mutated genes that belong to the same functional gene sets.
Genetic differences between mantle cell lymphoma and other lymphomas
In order to better understand the genetic differences between common non Hodgkin lymphomas, we analyzed exome sequencing data that we 13,17 and others 5,34-37 have generated from Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL). We identified all genes that were mutated at a frequency of 10% or higher in at least one tumor type and differentially mutated among at least one of the lymphoma types (P<0.05, Fisher's exact test). We plotted the relative frequencies of these genes for mantle cell lymphoma, Burkitt lymphoma and the molecular subgroups of DLBCL in Figure 2 .
We found a number of genes that were predominantly mutated in each disease. Mutations in ATM, CCND1, and RB1 occurred mostly in mantle cell lymphoma. Mutations in ID3 and MYC occurred predominantly in Burkitt lymphoma. Mutations in PIM1, BCL2 and CREBBP occurred 1 1 mostly in DLBCLs. A number of genes had overlapping patterns of mutations between two or more of the diseases, including TP53, GNA13, ARID1A and SMARCA4.
We further examined the association between individual genes that were recurrently mutated in these diseases (Supplement Figure 2 ). We found that ATM and RB1 mutations tended to co-occur in the same cases, reflecting their involvement in the DNA damage response and its importance in mantle cell lymphoma.
Epigenetic profiling of normal B cells and its relationship to gene expression
Gene expression and replication must be preceded by conformational changes in the chromatin to an open state 38 . We sought to define the relationship between the epigenetically determined chromatin state of primary mature B cells and the lymphomas that are thought to arise from them.
We performed FACS-sorting of normal naïve B cells, germinal center B cells and memory B
cells from otherwise normal individuals undergoing tonsillectomy (>95% purity verified by flow cytometry in each case) 14 . We profiled the chromatin structure and epigenetic state of the normal B cells through ChIP-seq on 6 different markers: H3K4me1, H3K4me3, H3Ac, H3K27me3, H4K36me3, and PolII. These markers collectively identify a comprehensive epigenetic portrait of these primary human cells. A few of these markers have been published previously in B cells, and the identified regions overlap strongly with our data 7 .
We plotted ( Figure 3a ) the aggregate density for each of the six markers associated with gene expression over a range from 2kb upstream to 10 kb downstream of all CCDS-annotated transcription start sites (TSS). Consistent with work in other cell types 38,39 , we found that H3K4me1 and H3Ac exhibited strong peaks before and after the TSS, PolII and H3K4me3 peaked directly at the TSS, and H3K36me3 exhibited elevated levels through the gene body ( Figure 3a) , reflecting transcriptionally active genes. H3K4me3 levels declined rapidly over the gene body, consistent with the notion that it marks promoter sites. The repressive marker H3K27me3 also was elevated before and after the TSS, an indication of the transcriptionally inactive genes.
We further plotted the chromatin epigenetic marker profiles around the transcription start sites for both highly and lowly expressed genes for each cell type 12 . We observed similar patterns in both cell types (Figure 3b ). The genes that were expressed the most highly in these B cells were highly associated (P<10 -6 , Pearson correlation test and Kolmogorov-Smirnov test) with the epigenetic alterations that identify open chromatin (H3K4Me1, H3K4Me3, H3Ac, H3K36Me3).
Conversely, the epigenetic alteration associated with closed chromatin (H3K27Me3) was found to be highly associated with repressed gene expression. The markers H3K4Me1, H3Ac and H3K36Me3 were most strongly associated with the gene body whereas H3K4Me3 was most strongly associated with promoter regions, as has been described previously 38 .
Role of B-cell differentiation stage in mantle cell lymphoma
Although B cell differentiation state is the basis for classifying lymphomas, the extent to which it is related to the molecular profiles of mantle cell lymphoma and other lymphomas has not been fully defined. In order to investigate this further, we examined the relationship between differentially activated chromatin marks between cell types and gene expression in the tumors of corresponding cell-of-origin (Figure 4a ). Based on the observed patterns of distribution of chromatin marks and the body of the gene, we defined open chromatin in all gene regions as a combination of marks corresponding to H3K36me3, H3ac, and H3K4me1. Differential chromatin levels for each gene were calculated by computing the difference of total number of aligned ChIP-seq reads from naïve and germinal center B cells that fell within the gene region, normalized by the length of the gene and the sequencing library size, similar to methods described previously (Supplement Table 4 ) 38 .
We examined the gene expression profiles of mantle cell lymphomas 18 and Burkitt lymphomas 31 performed on the same microarray platform. We observed a striking overlap (Figure 4a 
Epigenetic profiling of normal B cells and its relationship to mutations in lymphoma
We next examined the association between the mutational patterns observed in mantle cell were not associated with expression differences of these genes in the normal B cells (Figure 4b ).
In addition, those genes mutated in both BL and MCL without significant differences in mutation rate did not show significant differences in open chromatin between the corresponding normal B cell types.
DISCUSSION
Our data identifies the genetic heterogeneity underlying mantle cell lymphoma and implicates a number of novel genes in the development of the disease. Our study overlapped significantly with recently published studies of 29 tumor exomes 40 and eighteen transcriptomes 2,39 (e.g. ATM, CCND1, TP53, WHSC1, MLL2, NOTCH1, UBR5) and targeted sequencing studies (e.g.
BIRC3 41 , ATM and TP53 42 ). Our work implicates other mutated genes in the mantle cell lymphoma including RB1, POT1, ROBO2, SMARCA4, and MLL3. Similar to other lymphomas 13 , our data indicate a striking heterogeneity underlying mantle cell lymphomas, with relatively few genes mutated in more than 10% of the cases. While our data indicate a paucity of activating mutations in oncogenes that can be readily targeted therapeutically, a functional analysis of gene mutations implicates cell cycle progression, cell adhesion, and signal transduction as broad oncogenic processes that could be targeted.
If the acquisition of somatic mutations in tumors was completely stochastic, then one might expect that virtually every oncogene and tumor suppressor gene to be involved in most cancers. Chromatin structure has been shown to be a potential determinant of local mutation rates in different cancers 8, 10 . One recent study examined, at megabase scale, the relationship between relative mutational rates across the genome and corresponding chromatin structure 8 . It found that genomic regions of higher SNV density associate with more closed chromatin.
Our study is, to our knowledge, the first to elucidate the relationship between differential genelevel mutation rates between two cancer types (MCL and BL) and the difference between chromatin states of their corresponding normal cells of origin (naïve and germinal center B cells). Our data indicate that at the gene level, the epigenetically defined differences in chromatin structure between Naïve and Germinal Center B cells is independently associated with both expression profiles and mutational profiles of B cell lymphomas derived from those cell types.
Mutation of chromatin modifying genes has been found to be a recurrent feature of many cancers. In lymphomas, EZH2 mutations have been shown to modify H3K27me3, a process that might influence lymphoid transformation in germinal center derived B cells. The role of transcription-associated mutagenesis has been described in prokaryotes 47 and yeast 48 . While it is possible that similar mechanisms underlie cancers, the association between chromatin structure and mutation rates is not explained by transcription alone. There was no relationship between differential gene expression and mutation, suggesting that other unknown mechanisms underlie the association between mutations and chromatin structure.
Our study identifies the epigenetically defined chromatin structure of normal B cells as a common denominator of both expression profiles and mutational profiles of B cell lymphomas.
This work thus provides an important starting point for understanding the genetic diversity of mantle cell lymphomas and the interplay between genetic and epigenetic alterations in cancer. CCND1  RB1  CTNNA2  WHSC1  ATM  ZNF117   GRIN2A  ZNF91  SMARCA4  ACAD9  FTCD  ID3  COL4A2  SLC29A2  BTG2  PCBP1  PTPRN  CAD  DTX1  MYC  GNA13  ARID1A  RYR1   TRRAP  CREBBP  BCL6  TLN2  SGK1  FIGN  GRIA2  BCL7A  TSHZ2  EPHA3  MIB1  DYNC1H1  PIK3CD  FANCD2  LPHN2  DYNC1I1  WDR66  LIFR  BCL2  TP53  PCDHB3  PIM1  DMXL1  ANKRD44  LRIG3  AFAP1L2  CD79B  KLHL14  NIPBL  MYD88  CDC123 EZH2 BIRC3 0% 50% 100% H3ac H3K4me1 Chromatin Markers in Normal B Cells
Conflict-of-interest
Higher Gene Expression
Lower Gene Expression
Higher Chromatin Marker Expression
Lower Chromatin Marker Expression
